Patients with idiopathic pulmonary fibrosis (IPF) are prone to depression and anxiety, which clearly affects their quality of life  — regardless of age, gender or disease’s severity as measured in pulmonary function tests, researchers in Korea report. The scientists also suggest that these people may benefit from cognitive behavioral therapy…
Depression and Anxiety Common in IPF Patients with Impact on Quality of Life, Study Finds
03 As my PF worsens, the list of things I’m able to do and places I’m able to go grows smaller. I’m sure as a patient and a caregiver, you know exactly what I mean.  Grieving as my PF worsens I grieve for all I’m not able to…
Pulmonary Fibrosis Symptoms: Fatigue
There are many symptoms associated with pulmonary fibrosis (PF), but fatigue is often cited as one of the most difficult to deal with by those living with the disease. MORE: Nine steps for managing pulmonary fibrosis Fatigue in pulmonary fibrosis goes much further than simply being tired and often can’t…
For those of you familiar with idiopathic pulmonary fibrosis (IPF), or any interstitial lung disease (ILD), actually, you will likely know what a pulmonary function test is. If you are a patient with any type of ILD, chances are you have had a pulmonary function test, or many,…
The Pulmonary Fibrosis Foundation (PFF) has announced its keynote speakers for the upcoming PFF Summit 2017, a biennial meeting set for Nov. 9-11 in Nashville, Tennessee. During the event, physicians and researchers will present their most current work on pulmonary fibrosis (PF), stem cell therapies, medical tourism and advances in…
Prometic Gets FDA Nod to Initiate Phase 2/3 Trial of PBI-4050 Combined with Ofev in IPF Patients
A Phase 2/3 clinical trial of PBI-4050, a potential new therapy for idiopathic pulmonary fibrosis (IPF), has been approved by the U.S. Food and Drug Administration (FDA), according to Prometic Life Sciences. The FDA has granted the drug candidate investigational new drug (IND) status, which facilitates clinical research. The Phase 2/3…
Before my diagnosis of idiopathic pulmonary fibrosis (IPF) nearly 18 months ago, I would have never considered myself to be an anxious person. The older I get and the more people I meet, including those who are sick and those who aren’t, I’m realizing how common it…
Clinical trial results of Patara Pharma’s inhaled therapy candidate PA101 for chronic cough caused by idiopathic pulmonary fibrosis (IPF) indicate the medication reduces cough in a disease-specific manner. The findings, published in the journal The Lancet Respiratory Medicine, were derived from a Phase 2 trial (NCT02412020) of…
Idiopathic Pulmonary Fibrosis in a Nutshell
Idiopathic pulmonary fibrosis is a relatively rare and serious condition. Although men tend to be affected more than women, anyone can get the disease.  Some risk factors for IPF are smoking, working with environmental pollutants, acid reflux, and a family history of the disease. MORE: Simple facts about idiopathic pulmonary…
If you’ve been diagnosed with pulmonary fibrosis, it’s likely that your healthcare team has mentioned pulmonary rehabilitation. But what is it and why do you need to do it? MORE: Eight tips for protecting your lungs from unhealthy air Pulmonary rehabilitation is a program that combines education, support, and exercise. The goal of…
Your PF Community
Recent Posts
- Gut bacteria B. adolescentis may be new preventive treatment for PF January 7, 2026
- On my diagnosis journey, I felt like I was moving in slow motion January 6, 2026
- Amid a sea of data, the PF community is critical in the search for a cure December 23, 2025
- FDA approves Jascayd for adults with progressive pulmonary fibrosis December 23, 2025
- Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data December 17, 2025
